7 2009 7 15 01. 1 02. 1 03. 2 04. 3 05. 4 06. 4 07. 5 08. 6 09. 6 10. 7 11. 7 12. 8 13. 9 14. 9 15. 10 16. 10 17. 11 18 11 19 12 20. 13
2 10 HIRFL-CSR) 2 10 2006 11 70 X 2006 11 2008 2009 5.4 AVEO 6 (HIM) 1
AVEO 95% AVEO HER2 KRAS P13 P53) Herceptin AVEO 2009 4.8 αvβ3 2
αvβ3 avβ3 αvβ3 VEGF VEGF αvβ3 v p3 αvβ3 2009 6.11 6 26 28 2009 CT CT 3
2009 6.29 45 TOGA 13.8 HER2 26% HER2G 16 ATLAS 4.8,. 2009 6.29 11 9 13 10 6.91/10 5% 5 2 15 34 50 ~70, 40 0.3/10 ~0.5/10 4
2/10 7/10 50% 20095.19 EGCG) (CLL) 33 8 olyphenone EGCG) 400 2000 2000 EGCG EGCG 5
20095.31,, 2009 2009 7.1 RAL RAL 450 100 Peter parker 6
Marisa Martin-Fermandez 2009 6 29 16 2009;6.18 ips 4 3 ips 7
RB1 RBI RB1 RBI RBI RBI RBI 2009 4.7 (VEGF) p53 2008 C E Y 0.25 / ~10 HepG-2 90% VEGr p53 VEGF p53 VEGF 2009;4.15 8
5 MRI 2009;5.8 600 13.8 2.7 HER2 HER2 9
80 2009 6.2 17 2009 6.19 RNA RNA 10
DNA RNA122 RNA 2 2009 6.1 730 5 6 12 3 3 4 2009 6.2 11
2009;6.5 JunB, HSCs JunB HSCs HSCs 6 12 JunB HSCs JunB HSCs JunB, HSCs Notch TGF-beta Emmanuelle Passegue HSCs Cancer Cell 2009;4-7 12
P53 p53 (SUZ) p53 20 p53 p53 p53 p53 p53 p53 p53 Cancer Call 2009;6-2 13